Literature DB >> 31081722

Thyroid and Cardiovascular Disease: Research Agenda for Enhancing Knowledge, Prevention, and Treatment.

Anne R Cappola1, Akshay S Desai2, Marco Medici3, Lawton S Cooper4, Debra Egan5, George Sopko4, Glenn I Fishman6, Steven Goldman7, David S Cooper8, Samia Mora9, Peter J Kudenchuk10, Anthony N Hollenberg11, Cheryl L McDonald4, Paul W Ladenson8.   

Abstract

Thyroid hormones have long been known to have a range of effects on the cardiovascular system. However, significant knowledge gaps exist concerning the precise molecular and biochemical mechanisms governing these effects and the optimal strategies for management of abnormalities in thyroid function in patients with and without preexisting cardiovascular disease. In September 2017, The National Heart, Lung, and Blood Institute convened a Working Group with the goal of developing priorities for future scientific research relating thyroid dysfunction to the progression of cardiovascular disease. The Working Group reviewed and discussed the roles of normal thyroid physiology, the consequences of thyroid dysfunction, and the effects of therapy in three cardiovascular areas: cardiac electrophysiology and arrhythmias, the vasculature and atherosclerosis, and the myocardium and heart failure. This report describes the current state of the field, outlines barriers and challenges to progress, and proposes research opportunities to advance the field, including strategies for leveraging novel approaches using omics and big data. The Working Group recommended research in three broad areas: 1) investigation into the fundamental biology relating thyroid dysfunction to the development of cardiovascular disease and into the identification of novel biomarkers of thyroid hormone action in cardiovascular tissues; 2) studies that define subgroups of patients with thyroid dysfunction amenable to specific preventive strategies and interventional therapies related to cardiovascular disease; and 3) clinical trials focused on improvement in cardiovascular performance and cardiovascular outcomes through treatment with thyroid hormone or thyromimetic drugs.

Entities:  

Keywords:  arrhythmia; atherosclerosis; heart failure; lipid; low T3 syndrome; subclinical hyperthyroidism; subclinical hypothyroidism

Year:  2019        PMID: 31081722      PMCID: PMC6913785          DOI: 10.1089/thy.2018.0416

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  122 in total

1.  Reductions in serum levels of LDL cholesterol, apolipoprotein B, triglycerides and lipoprotein(a) in hypercholesterolaemic patients treated with the liver-selective thyroid hormone receptor agonist eprotirome.

Authors:  Bo Angelin; Jens D Kristensen; Mats Eriksson; Bo Carlsson; Irwin Klein; Anders G Olsson; E Chester Ridgway; Paul W Ladenson
Journal:  J Intern Med       Date:  2014-05-16       Impact factor: 8.989

2.  Narrow individual variations in serum T(4) and T(3) in normal subjects: a clue to the understanding of subclinical thyroid disease.

Authors:  Stig Andersen; Klaus Michael Pedersen; Niels Henrik Bruun; Peter Laurberg
Journal:  J Clin Endocrinol Metab       Date:  2002-03       Impact factor: 5.958

3.  The significance of alterations in serum lipids in thyroid dysfunction. I. The relation between serum lipoproteins, carotenoids and vitamin A in hypothyroidism and thyrotoxicosis.

Authors:  K W Walton; D A Campbell; E L Tonks
Journal:  Clin Sci       Date:  1965-10       Impact factor: 6.124

4.  Pulmonary hypertension is frequent in hyperthyroidism and normalizes after therapy.

Authors:  Maurizio Marvisi; Paolo Zambrelli; Marco Brianti; Giuseppe Civardi; Rinaldo Lampugnani; Roberto Delsignore
Journal:  Eur J Intern Med       Date:  2006-07       Impact factor: 4.487

5.  Prospective echocardiographic evaluation of patients with endogenous subclinical hyperthyroidism and after restoring euthyroidism.

Authors:  Grzegorz Kaminski; Dariusz Michalkiewicz; Karol Makowski; Zbigniew Podgajny; Norbert Szalus; Marek Ruchala; Ewelina Szczepanek; Grzegorz Gielerak
Journal:  Clin Endocrinol (Oxf)       Date:  2011-04       Impact factor: 3.478

6.  Long-term amiodarone administration remodels expression of ion channel transcripts in the mouse heart.

Authors:  Sabrina Le Bouter; Aziza El Harchi; Céline Marionneau; Chloé Bellocq; Arnaud Chambellan; Toon van Veen; Christophe Boixel; Bruno Gavillet; Hugues Abriel; Khai Le Quang; Jean-Christophe Chevalier; Gilles Lande; Jean J Léger; Flavien Charpentier; Denis Escande; Sophie Demolombe
Journal:  Circulation       Date:  2004-11-01       Impact factor: 29.690

7.  Dyslipidemia in subclinical hypothyroidism requires assessment of small dense low density lipoprotein cholesterol (sdLDL-C).

Authors:  Maida Seferovic Saric; Miljenka-Jelena Jurasic; Slavica Sovic; Bojana Kranjcec; Tatjana Glivetic; Vida Demarin
Journal:  Rom J Intern Med       Date:  2017-09-26

Review 8.  Amiodarone and the thyroid.

Authors:  Shehzad Basaria; David S Cooper
Journal:  Am J Med       Date:  2005-07       Impact factor: 4.965

9.  Levothyroxine treatment of subclinical hypothyroidism, fatal and nonfatal cardiovascular events, and mortality.

Authors:  Salman Razvi; Jolanta U Weaver; Timothy J Butler; Simon H S Pearce
Journal:  Arch Intern Med       Date:  2012-05-28

Review 10.  Multi-omics approaches to disease.

Authors:  Yehudit Hasin; Marcus Seldin; Aldons Lusis
Journal:  Genome Biol       Date:  2017-05-05       Impact factor: 13.583

View more
  17 in total

Review 1.  REPRODUCTIVE TOXICOLOGY: Pregnancy exposure to endocrine disrupting chemicals: implications for women's health.

Authors:  Diana K Haggerty; Kristen Upson; Diana C Pacyga; J Ebba Franko; Joseph M Braun; Rita S Strakovsky
Journal:  Reproduction       Date:  2021-10-07       Impact factor: 3.923

2.  The effect of Thyroid Autoimmunity on Dyslipidemia in patients with Euthyroid Hashimoto Thyroiditis.

Authors:  Hasret Cengiz; Taner Demirci; Ceyhun Varim; Ali Tamer
Journal:  Pak J Med Sci       Date:  2021 Sep-Oct       Impact factor: 1.088

3.  Thyroid storm with encephalopathy and cardiovascular symptoms refractory to medical management in an adolescent.

Authors:  Jigar C Chauhan; Meg Frizzola; Kimberly McMahon; Sarah Perry; James H Hertzog
Journal:  Int J Crit Illn Inj Sci       Date:  2020-03-06

4.  Evaluation of Thyroid Function in Patients Hospitalized for Acute Heart Failure.

Authors:  Ana Rita Leite; João Sérgio Neves; Marta Borges-Canha; Catarina Vale; Madalena von Hafe; Davide Carvalho; Adelino Leite-Moreira
Journal:  Int J Endocrinol       Date:  2021-03-31       Impact factor: 3.257

5.  Clinical Parameters Are More Likely to Be Associated with Thyroid Hormone Levels than with Thyrotropin Levels: A Systematic Review and Meta-Analysis.

Authors:  Stephen P Fitzgerald; Nigel G Bean; Henrik Falhammar; Jono Tuke
Journal:  Thyroid       Date:  2020-06-04       Impact factor: 6.568

6.  Thyroid testing paradigm switch from thyrotropin to thyroid hormones-Future directions and opportunities in clinical medicine and research.

Authors:  Stephen P Fitzgerald; Nigel G Bean; James V Hennessey; Henrik Falhammar
Journal:  Endocrine       Date:  2021-08-27       Impact factor: 3.633

Review 7.  The Association with Subclinical Thyroid Dysfunction and Uric Acid.

Authors:  Yuling Xing; Linlin Yang; Jing Liu; Huijuan Ma
Journal:  Int J Endocrinol       Date:  2021-12-13       Impact factor: 3.257

8.  Cardiovascular Events in Patients with Thyroid Storm.

Authors:  Zainulabedin Waqar; Sindhu Avula; Jay Shah; Syed Sohail Ali
Journal:  J Endocr Soc       Date:  2021-03-11

Review 9.  Levothyroxine for the Treatment of Subclinical Hypothyroidism and Cardiovascular Disease.

Authors:  Laura Y Sue; Angela M Leung
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-21       Impact factor: 5.555

10.  Use of Statins Among Patients Taking Levothyroxine: an Observational Drug Utilization Study Across Sites.

Authors:  Thaer Idrees; Wesley H Prieto; Sabina Casula; Aswathy Ajith; Matthew Ettleson; Flavia A Andreotti Narchi; Pedro S T Russo; Fernando Fernandes; Julie Johnson; Anoop Mayampurath; Rui M B Maciel; Antonio C Bianco
Journal:  J Endocr Soc       Date:  2021-03-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.